Broth Culture Testing for Interstitial Cystitis — CPB 0695 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0695 for broth culture testing for interstitial cystitis, effective November 26, 2025. Claims hitting CPT 87086, 87088, and the full 87181–87190 susceptibility range under ICD-10 N30.10 or N30.11 face automatic denial.

Aetna, a CVS Health company, classifies broth culture testing for interstitial cystitis as experimental, investigational, and unproven under CPB 0695 in Aetna's system. That classification isn't new in spirit, but the November 26, 2025 update formalizes the coverage policy and brings the full code set into scope — including HCPCS P7001 and 12 CPT codes spanning bacterial cultures and antimicrobial susceptibility studies. If your urology or urogynecology billing team is running these tests under interstitial cystitis diagnoses, expect denials. The question is whether your team knows that before the claims go out.

Quick-Reference Table

Aetna Broth Culture Testing Coverage Criteria and Medical Necessity Requirements 2025

The Aetna broth culture testing coverage policy under CPB 0695 is straightforward: there are no covered indications. Aetna finds no adequate clinical evidence that broth culture testing is effective for diagnosing or managing interstitial cystitis. That's the whole story on coverage — zero medical necessity pathway exists under this policy.

That matters because interstitial cystitis (chronic), coded as N30.10 and N30.11, is a diagnosis where some providers have used broth culture testing to investigate possible bacterial involvement. Aetna is saying the evidence doesn't support it. If your provider orders CPT 87086 (bacterial culture, quantitative colony count, urine) or CPT 87088 (culture with isolation and presumptive identification) alongside ICD-10 N30.10 or N30.11, the claim will not pass medical necessity review.

The susceptibility codes — CPT 87181 through 87190 — are equally affected. These codes typically follow a positive culture finding, but under this coverage policy, the underlying broth culture test itself is non-covered. That means downstream susceptibility billing also falls outside reimbursement when the context is an interstitial cystitis diagnosis.

There is no prior authorization pathway listed in this policy. That's not a loophole — it's because Aetna has ruled the test experimental. Prior authorization won't help you here. An experimental designation means the claim denial happens at the coverage level, not the authorization level.

Aetna Broth Culture Testing Exclusions and Non-Covered Indications

Aetna's position on broth culture testing for interstitial cystitis is unambiguous. The payer considers this testing experimental, investigational, and unproven. That's three separate labels, and each one carries the same practical outcome: no reimbursement.

The clinical rationale in CPB 0695 is that available evidence does not adequately demonstrate the effectiveness of broth culture testing in diagnosing or managing interstitial cystitis. Aetna isn't saying the test is harmful. They're saying the evidence base for using it in this specific clinical context is insufficient to support coverage.

This is worth flagging to your medical director and ordering providers. The denial isn't administrative — it's a coverage exclusion. Appeals based on medical necessity documentation won't change the outcome unless the policy itself changes. If a provider believes this testing is clinically warranted, that conversation needs to happen before the order is placed, not after the claim is denied.

Coverage Indications at a Glance

Aetna Broth Culture Testing Billing Guidelines and Action Items 2025

The effective date of November 26, 2025 has passed. If your team hasn't already adjusted workflows for this policy, do it now.

The broader broth culture billing picture is also worth revisiting. CPT 87086 and 87088 are legitimate codes for routine urine cultures in other clinical contexts — UTI workup, kidney infection, and similar. The exclusion here is specific to the interstitial cystitis diagnosis codes N30.10 and N30.11. Make sure your team understands that distinction so you're not over-blocking legitimate culture billing.

CPT, HCPCS, and ICD-10 Codes for Broth Culture Testing Under CPB 0695

All codes listed below are drawn directly from Aetna CPB 0695. Every one of these codes falls under the experimental/not covered designation when billed in the context of interstitial cystitis.

Not Covered CPT Codes — Broth Culture and Susceptibility Testing for Interstitial Cystitis

Not Covered HCPCS Codes

Key ICD-10-CM Diagnosis Codes — Interstitial Cystitis

These are the diagnosis codes that trigger the CPB 0695 exclusion. Broth culture testing billed under either code is non-covered.

One note on the susceptibility codes: CPT 87181–87190 each represent different methodological approaches to antimicrobial susceptibility testing. Aetna's policy lists all of them under CPB 0695, which suggests the exclusion is broad by design. Any susceptibility testing that follows a broth culture ordered for an interstitial cystitis workup falls within the experimental designation. Don't try to split the billing by separating the culture from the susceptibility study — the denial will follow the diagnosis.